Text Size

Serum Omentin-1 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

This study is currently recruiting participants.
Verified October 2012 by Kocaeli Derince Education and Research Hospital
Sponsor:
Information provided by (Responsible Party):
Kocaeli Derince Education and Research Hospital
ClinicalTrials.gov Identifier:
NCT01701830
First received: October 3, 2012
Last updated: October 4, 2012
Last verified: October 2012
History of Changes
  Purpose

The aim of the study is to evaluate whether a low level of serum omentin-1 is associated with carotid atherosclerosis and mediated by inflammation.


Condition
Non-diabetic Chronic Kidney Disease
Atherosclerosis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Relationship Between Serum Omentin-1 and IL-6 and Carotid Atherosclerosis In Non-Diabetic Chronic Kidney Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Kocaeli Derince Education and Research Hospital:

Estimated Enrollment: 85
Study Start Date: October 2012
Estimated Study Completion Date: May 2013
Groups/Cohorts
Case Group
Patients with chronic kidney disease of stage 3-4.
Control group
30 healthy subject

Detailed Description:

Atherosclerotic cardiovascular disease is markedly increased in chronic kidney disease. There are a lot of risk factor, along with conventional risk factors. Serum onemtin-1 is a adipokine and suggested as a new marker for vascular disease.It has some anti-atherogenic properties. Studies investigating serum omentin-1 level have usually conducted in patients with diabetes mellitus.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Department of Nephrology, Check-up clinic

Criteria

Inclusion Criteria:

  • between ages of 18 - 65 years old chronic kidney disease of stage 3-4

Exclusion Criteria:

  • Chronic kidney disease of stage 5
  • The history of ischemic cardiovascular disease (myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization)
  • Severe heart failure
  • Stage 2 hypertension
  • Diabetes mellitus
  • Corticosteroid therapy
  • Severe hepatic disease
  • Smoking
  • Inflammatory disease
  • Acute infectious disease
  • Malignancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01701830

Locations
Turkey
Department of Nephrology, Check-up Clinic,Kocaeli Derince Education and Traning Hospital Recruiting
Izmit, Kocaeli, Turkey, 41100
Contact: Rabia TERZI, MD     90262 317 80 00 ext 8110     drrabia1@yahoo.com    
Principal Investigator: Erkan SENGUL, MD            
Sub-Investigator: Gokhan DUYGULU, MD            
Sub-Investigator: Sevim DINDAR, MD            
Sub-Investigator: Fatih BUNUL, MD            
Sponsors and Collaborators
Kocaeli Derince Education and Research Hospital
Investigators
Principal Investigator: Erkan SENGUL, MD Kocaeli Derince Education and Training Hospital
  More Information

No publications provided

Responsible Party: Kocaeli Derince Education and Research Hospital
ClinicalTrials.gov Identifier: NCT01701830     History of Changes
Other Study ID Numbers: 2012/02
Study First Received: October 3, 2012
Last Updated: October 4, 2012
Health Authority: Turkey: Ministry of Health

Keywords provided by Kocaeli Derince Education and Research Hospital:
omentin-1
carotid atherosclerosis
kidney disease

Additional relevant MeSH terms:
Atherosclerosis
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
Carotid Artery Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
 Cardiovascular Diseases
Urologic Diseases
Renal Insufficiency
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on May 19, 2013